Sol Jin

Sol Jin

Auto-generated profile, based on publicly available information

Sol Jin

Department of Infectious Diseases, Kosin University Gospel Hospital, Busan, Korea

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2021 in Viruses
Verified
Journal Article
Open access
PDF file
JKJi-Soo Kwon
Ji-Soo Kwon
SJSol Jin
Sol Jin
JKJi-Yeun Kim
Ji-Yeun Kim
SRSang-Hyun Ra
Sang-Hyun Ra
TKTaeeun Kim
Taeeun Kim
SKSung-Han Kim
Sung-Han Kim
Significant progress has been made on the molecular biology of the severe fever with thrombopenia virus (SFTSV); however, many parts of the pathophysiological mechanisms of mortality in SFTS remain unclear. In this study, we investigated virologic and immunologic factors for fatal outcomes of patients with SFTS. We prospectively enrolled SFTS patients admitted from July 2015 to October 2020. Plasma samples were subjected to SFTSV RNA RT-PCR, multiplex microbead immunoassay for 17 cytokines, and IFA assay. A total of 44 SFTS patients were enrolled, including 37 (84.1%) survivors and 7 (15.9%) non-survivors. Non-survivors had a 2.5 times higher plasma SFTSV load than survivors at admission (p < 0.001), and the viral load in non-survivors increased progressively during hospitalization. In addition, non-survivors did not develop adequate anti-SFTSV IgG, whereas survivors exhibited anti-SFTSV IgG during hospitalization. IFN-α, IL-10, IP-10, IFN-γ, IL-6, IL-8, MCP-1, MIP-1α, and G-CSF were significantly elevated in non-survivors compared to survivors and did not revert to normal ranges during hospitalization (p < 0.05). Severe signs of inflammation such as a high plasma concentration of IFN-α, IL-10, IP-10, IFN-γ, IL-6, IL-8, MCP-1, MIP-1α, and G-CSF, poor viral control, and inadequate antibody response during the disease course were associated with mortality in SFTS patients.

11 December 2020 in Medicine
Verified
Journal Article
Open access
SJSol Jin
Sol Jin
JLJin-Young Lee
Jin-Young Lee
JPJi Young Park
Ji Young Park
MJMin Ji Jeon
Min Ji Jeon
Carbapenemase-producing organisms (CPO) have been identified as an urgent healthcare threat. Various methods have been used for the detection of CPO using rectal swabs. Recently, an on-demand polymerase chain reaction (PCR) assay, namely, the Xpert Carba-R assay, that requires less than an hour of turnaround time, had been developed for CPO detection in clinical samples. This study focused on the use of this assay to determine the intestinal colonization rate of CPO in patients admitted to emergency rooms (ERs). A retrospective review of medical records was conducted at a tertiary hospital between July 2017 and June 2018. CPO screening using rectal swabs was performed for patients transferred from other hospitals or for those who tested positive in CPO culture tests in the previous three months. The Xpert Carba-R assay and culture tests were used as the CPO screening methods, and the results of both tests were compared. Medical records of 705 patients admitted to our hospital during the study period were reviewed. Of these, 31 (4.4%) showed positive results for CPO using the Xpert Carba-R assay, and these patients were then transferred from the ERs to isolation rooms. Fifteen of the Xpert Carba-R assay-positive patients were also positive for the culture test; hence, early detection enabled the rapid isolation of CPO-infected patients and prevented the spread of the CPO. The Xpert Carba-R assay is a rapid test to identify and guide infection control programs to contain the spread of the rectal colonization of CPO within a hospital.

24 February 2023 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
YLYun Woo Lee
Yun Woo Lee
SLSo Yun Lim
So Yun Lim
SJSol Jin
Sol Jin
HPHye Jin Park
Hye Jin Park
HSHeungsup Sung
Heungsup Sung
YCYong Pil Chong
Yong Pil Chong
Yun Woo Lee, M.D., So Yun Lim, M.D., Sol Jin, M.D., Hye Jin Park, M.D., Heungsup Sung, M.D., Ph.D., Mi-Na Kim, M.D., Ph.D., Seongman Bae, M.D., Ph.D., Jiwon Jung, M.D., Ph.D., Min Jae Kim, M.D., Ph.D., Sung-Han Kim, M.D., Ph.D., Sang-Oh Lee, M.D., Ph.D., Sang-Ho Choi, M.D., Ph.D., Yang Soo Kim, M.D., Ph.D., and Yong Pil Chong, M.D., Ph.D.. Ann Lab Med 2023;43:381-5. https://doi.org/10.3343/alm.2023.43.4.381

31 March 2022 in Kosin Medical Journal
Verified
Journal Article
Open access
MJMinji Jeon
Minji Jeon
SJSol Jin
Sol Jin
JLJin-Young Lee
Jin-Young Lee
To overcome the coronavirus disease 2019 (COVID-19) pandemic, large-scale vaccination is proceeding worldwide. As of December 23, 2021, 10 novel vaccines against COVID-19 had been validated for use by the World Health Organization (WHO), including BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna), AZD1222 (AstraZeneca), and Ad26.COV2.S (Janssen). These novel vaccines against COVID-19 showed acceptable safety profiles in randomized clinical trials. Most adverse events following immunization (AEFIs) associated with these novel vaccines ranged from mild to moderate and improved within a few days after administration. However, serious adverse events associated with vaccines that were not observed in the clinical trials were reported in real-world data. Adverse events of special interest include not only anaphylaxis or neurologic disorders (such as Guillain-Barré syndrome, transverse myelitis, or seizure) but also myocarditis or pericarditis associated with the messenger RNA (mRNA) vaccines and thrombosis with thrombocytopenia syndrome associated with the adenovirus-vector vaccines. Although several fatal cases of serious AEFIs that may have been related to vaccination have been reported, it is recommended to continue vaccination because the benefits of vaccines’ preventive effects against COVID-19 outweigh the risks of rare serious adverse events. Long-term monitoring of various AEFIs and sharing of clinical experiences are necessary for safe and efficient large-scale vaccination.